Article thumbnail

Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis

By Avraham Beigelman, Cassandra L Mikols, Sean P Gunsten, Carolyn L Cannon, Steven L Brody and Michael J Walter
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2906448
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1997). A: Roxithromycin attenuates acid-induced cough and water-induced bronchoconstriction in children with asthma.
  2. (2002). Agapov E, Holtzman MJ: Viral induction of a chronic asthma phenotype and genetic segregation from the acute response.
  3. (2007). AL: Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy Asthma Proc
  4. (2001). Allegra L: Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med
  5. (2004). Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis.
  6. (2008). Bacharier LB: Cytokine response after severe respiratory syncytial virus bronchiolitis in early life.
  7. (2005). BK: Macrolides and airway inflammation in children. Paediatr Respir Rev
  8. (2006). Diagnosis and management of bronchiolitis. Pediatrics
  9. (2008). Effects of telithromycin in in vitro and in vivo models of lipopolysaccharide-induced airway inflammation. Chest
  10. (2001). Epidemiologic and clinical evidence of a respiratory syncytial virus-reactive airway disease link.
  11. (2006). Erakovic V: Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice.
  12. (2002). Erdemoglu AK: Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma.
  13. (1997). Geddes DM: Erythromycin and diffuse panbronchiolitis. Thorax
  14. (2008). Holtzman MJ: Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med
  15. (2009). Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis
  16. (2000). Ishizaki Y: Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol
  17. (2007). Koc N: Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial. Eur Respir J
  18. (1997). Kohlhase K: Respiratory syncytial virus-coded pediatric hospitalizations,
  19. (1994). Kuroume T: Roxithromycin reduces the degree of bronchial hyperresponsiveness in children with asthma. Chest
  20. (1980). LJ: Bronchiolitis-associated hospitalizations among US children,
  21. (2009). LJ: Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice.
  22. (2002). Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet
  23. (2009). Macrolide antibiotics inhibit respiratory syncytial virus infection in human airway epithelial cells. Antiviral Res
  24. (2009). MJ: Azithromycin Attenuates Airway Inflammation in a Noninfectious Mouse Model of Allergic Asthma. Chest
  25. (2003). MJ: IL-12 p40 homodimer-dependent macrophage chemotaxis and respiratory viral inflammation are mediated through IL-12 receptor beta 1. J Immunol
  26. (2006). MJ: IL-12 p80 is an innate epithelial cell effector that mediates chronic allograft dysfunction. Am J Respir Crit Care Med
  27. (2009). MJ: IL-12 p80-dependent macrophage recruitment primes the host for increased survival following a lethal respiratory viral infection. Immunology
  28. (2000). MR: Rates of hospitalization for respiratory syncytial virus infection among children in medicaid.
  29. (2002). Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest
  30. (2004). Papamichalopoulos A: Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J
  31. (2000). RB: Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA
  32. (2006). RB: The effect of telithromycin in acute exacerbations of asthma.
  33. (2000). Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med
  34. (1986). Risk of primary infection and reinfection with respiratory syncytial virus.
  35. (1998). Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro. Antimicrob Agents Chemother
  36. (2004). Rubinstein I: Low-dose, long-term macrolide therapy in asthma: An overview. Clin Mol Allergy
  37. (1996). S: Eosinophil apoptosis caused by theophylline, glucocorticoids, and macrolides after stimulation with IL-5. J Allergy Clin Immunol
  38. (1991). Satake T: Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest
  39. (2005). Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med
  40. (2001). SL: Effects of paramyxoviral infection on airway epithelial cell Foxj1 expression, ciliogenesis, and mucociliary function.
  41. (1995). Takeda T: The macrolide antibacterial roxithromycin reduces bronchial hyperresponsiveness and superoxide anion production by polymorphonuclear leukocytes in patients with asthma.
  42. (1998). Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice.
  43. (2004). TJ: Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med
  44. (2009). TV: The severity-dependent relationship of infant bronchiolitis on the risk and morbidity of early childhood asthma. J Allergy Clin Immunol
  45. (2008). Uiterwaal CS, Kimpen JL: Azithromycin does not improve disease course in hospitalized infants with respiratory syncytial virus (RSV) lower respiratory tract disease: a randomized equivalence trial. Pediatr Pulmonol
  46. Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.
  47. (2004). Wong WS: Anti-inflammatory effects of mitogen-activated protein kinase kinase inhibitor U0126 in an asthma mouse model.
  48. (2007). Wong WS: Glycogen synthase kinase-3beta inhibition attenuates asthma in mice.
  49. (1996). Zurlinden E: Singledose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob Agents Chemother